Statking Consulting, Inc.
Genesis Drug Discovery & Development (GD3) is a fully integrated CRO supporting drug discovery programs from target discovery through IND filing and clinical trials. They leverage decades of industry experience to provide high-quality, tailored services across various divisions including chemistry, biochemistry, bioanalytical, disease modeling, and preclinical toxicology. Their mission is to advance therapeutic programs for the benefit of patients, with a focus on scientific excellence, collaboration, and regulatory compliance.
Industries
Nr. of Employees
small (1-50)
Statking Consulting, Inc.
Robbinsville, New Jersey, United States, North America
Products
Compound screening libraries
Curated compound collections made available for screening and early discovery campaigns.
Compound screening libraries
Curated compound collections made available for screening and early discovery campaigns.
Services
Hit-to-lead, lead optimization, structure-based design, custom organic synthesis, asymmetric synthesis, metabolite and probe synthesis, stable isotope labeling and compound characterization.
Synthetic route discovery, process optimization, API specification development and large‑scale synthesis with appropriate facilities and equipment.
Analytical method development and sample analysis using NMR, HPLC, LC‑MS, GC‑MS, LC‑MS/MS quantitation, tissue qualification, method validation and statistical PK/TK analysis for regulated and non‑regulated studies.
Bioconjugation, linker‑payload design and synthesis, ADC process research, purification and analytic services, and mechanism‑of‑action investigations for ADC programs.
Molecular biology, biochemical and cell‑based assay development including reporter bioassays, HTRF/TR‑FRET, fluorescence and luminescence assays, cell line development, ADME/permeability assays and method qualification and transfer.
In vitro ADME, in vivo DMPK, exposure and bioavailability studies, biodistribution, PD biomarker investigations and dose–exposure PK/PD studies to support candidate selection and IND enabling packages.
Hit-to-lead, lead optimization, structure-based design, custom organic synthesis, asymmetric synthesis, metabolite and probe synthesis, stable isotope labeling and compound characterization.
Synthetic route discovery, process optimization, API specification development and large‑scale synthesis with appropriate facilities and equipment.
Analytical method development and sample analysis using NMR, HPLC, LC‑MS, GC‑MS, LC‑MS/MS quantitation, tissue qualification, method validation and statistical PK/TK analysis for regulated and non‑regulated studies.
Bioconjugation, linker‑payload design and synthesis, ADC process research, purification and analytic services, and mechanism‑of‑action investigations for ADC programs.
Molecular biology, biochemical and cell‑based assay development including reporter bioassays, HTRF/TR‑FRET, fluorescence and luminescence assays, cell line development, ADME/permeability assays and method qualification and transfer.
In vitro ADME, in vivo DMPK, exposure and bioavailability studies, biodistribution, PD biomarker investigations and dose–exposure PK/PD studies to support candidate selection and IND enabling packages.
Expertise Areas
- Medicinal chemistry and small‑molecule discovery
- Process chemistry and API scale‑up
- Antibody–drug conjugate (ADC) development
- DMPK and regulated bioanalysis (LC‑MS/MS)
Key Technologies
- Liquid chromatography–mass spectrometry (LC‑MS/MS)
- High‑performance liquid chromatography (HPLC)
- Nuclear magnetic resonance spectroscopy (NMR)
- Gas chromatography–mass spectrometry (GC‑MS)
News & Updates
GD3 offers an optic nerve crush model to study neuronal injury, regeneration, and biomarkers related to glaucoma and neurodegenerative diseases.
GD3 provides a model to study retinal leakage and inflammation in age-related macular degeneration using intravitreal VEGF injection.
GD3 offers an optic nerve crush model to study neuronal injury, regeneration, and biomarkers related to glaucoma and neurodegenerative diseases.
GD3 provides a model to study retinal leakage and inflammation in age-related macular degeneration using intravitreal VEGF injection.